Triple
T1103715
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Leqembi |
E25439
|
entity |
| Predicate | hasKeyClinicalTrial |
P23163
|
FINISHED |
| Object |
CLARITY AD
CLARITY AD is a pivotal phase 3 clinical trial that evaluated the efficacy and safety of the anti-amyloid Alzheimer’s disease drug lecanemab (Leqembi) in patients with early Alzheimer’s disease.
|
E125383
|
NE FINISHED |
Provenance (7 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69a49428d4448190b3b36991ceae87ce |
elicitation | completed |
| NER | batch_69a4b9c375848190baec4d534f489616 |
ner | completed |
| NED1 | batch_69ac4c4a402081908ee138257425a336 |
ned_source_triple | completed |
| NED2 | batch_69ac4d4cbed88190ac743160198493b2 |
ned_description | completed |
| NEDg | batch_69ac4ccf989c8190aed2ff01ad6fbcab |
nedg | completed |
| PD | batch_69a4b7472c848190b0643872f67084a2 |
pd | completed |
| PDg | batch_69a4b7da38888190a118ef20ce4ae9aa |
pdg | completed |
Created at: March 1, 2026, 7:43 p.m.